PARIS--(BUSINESS WIRE)--Regulatory News :
Cellectis SA (Paris:ALCLS) (Alternext: ALCLS.PA), a biopharmaceutical company focused on developing immunotherapies based on gene edited engineered CART-cells (UCART), today announced that three abstracts on the Company’s CART-cell development programs were accepted for presentation at the 56th Annual Meeting and Exposition of the American Society of Hematology (ASH) in San Francisco, December 6-9, 2014.
The abstracts are listed below and available on the ASH conference
website at:
https://ash.confex.com/ash/2014/webprogram/start.html
Poster Presentations
Title: “Multiplex Genome Editing As a Platform for “Off-the-Shelf” Adoptive CAR T-Cell Immunotherapies”
- Abstract Number: 1111
- Date: Saturday, December 6, 2014
- Presentation Time: 5:30 PM - 7:30 PM PST
Title: “Allogeneic T-Cells Targeting CD123 for Adoptive Immunotherapy of Acute Myeloid Leukemia (AML)”
- Abstract Number: 1116
- Date: Saturday, December 6, 2014
- Presentation Time: 5:30 PM - 7:30 PM PST
Title: “In Vivo Proof of Concept of Activity and Safety of UCART19, an Allogeneic ‘Off-the-Shelf’ Adoptive T-Cell Immunotherapy against CD19+ B-Cell Leukemias”
- Abstract Number: 4689
- Date: Monday, December 8, 2014
- Presentation Time: 6:00 PM - 8:00 PM PST
About Cellectis
Cellectis is a biopharmaceutical company
focused on developing immunotherapies based on gene edited engineered
CART-cells (UCART). The company’s mission is to develop a new generation
of cancer therapies based on engineered T-cells. Cellectis capitalizes
on its 14 years of expertise in genome engineering - based on its
flagship TALEN™ products and meganucleases and pioneering
electroporation PulseAgile technology - to create a new generation of
immunotherapies for treating leukemias and solid tumors. Cellectis’
adoptive cancer immunotherapy for chronic and acute leukemias is based
on allogeneic T-cell chimeric antigen receptor (CAR) technology. CAR
technologies are designed to target surface antigens expressed on cells.
Using its life-science-focused, pioneering genome-engineering
technologies, Cellectis’ goal is to create innovative products in
multiple fields and with various target markets.
Disclaimer
This press release and the information contained
herein do not constitute an offer to sell or subscribe, or a
solicitation of an offer to buy or subscribe for shares in Cellectis in
any country. This press release contains forward-looking statements that
relate to the Company’s objectives based on the current expectations and
assumptions of the Company’s management only and involve unforeseeable
risk and uncertainties that could cause the Company to fail to achieve
the objectives expressed by the forward-looking statements.